CrossBridge Bio is an innovative company focused on developing Antibody-Drug Conjugates (ADCs) with a platform that emphasizes stability, precise drug release, and mitigation of off-target effects. The company aims to revolutionize cancer therapeutics through its advanced technology and diverse antibody-payload pairings.

CrossBridge Bio

CrossBridge Bio | 903 followers on LinkedIn. CrossBridge Bio is a biotechnology company focused on developing innovative dual-payload ADC therapeutics. | CrossBridge Bio is a biotechnology company focused on developing innovative ADC therapeutics using our proprietary stable dual-linker payload technology.

Translational Oncology | Drug Discovery | In Vivo and In Vitro Pharmacology | Neuro Immunology I Neurodegeneration | Project Management & Research…

Veerakumar B.

Entrepreneur. Drug Developer. Doer.

Michael Torres

Biotech | VC | Investor

Damir Illich

Interesting coverage of CrossBridge Bio and their dual payload antibody-drug conjugates. The company will advance its lead candidate, the dual-payload ADC CBB-120 for the treatment of trophoblast cell-surface antigen 2 (TROP-2)-positive solid tumors, to investigational new drug (IND)-enabling studies. Safety testing in non-human primates is expected to start in 2025. We look forward to news in the future. #mabs https://lnkd.in/ebk-GJhJ

The Antibody Society

We're proud to announce non-dilutive funding to support CBB-120, our dual-payload ADC for Trop2+ cancers. Beyond CBB-120, we're building out our pipeline/platform and working with clinicians such as David S. Hong, MD & Martin Dietrich, MD, PhD , to ensure we build best-in-class assets to serve patients best. We're proud to be building here in #Texas ! Thank you Cancer Prevention and Research Institute of Texas for your support. Please reach out to our leadership team to learn more about investing/partnering opportunities: Michael Torres Daniel Pereira Abhishake Chhibber

I'm excited to share the story of building CrossBridge Bio with Kyoji Tsuchikama at #ASPET2024 . It all started with great science, in this case, Kyoji's novel linker that allows dual-payload ADCs. With great science, you need a great team. I'm privileged to have recruited folks like Daniel Pereira Morris Rosenberg Abhishake Chhibber to the team. More to come on the investor side of things, but suffice it to say, my team is thoughtful in utilizing our technology. It's attracting the right eyes! I look forward to sharing more!

We're looking forward to attending #ASCO24 this year. Don't hesitate to get in touch with our CEO ( Michael Torres ) and CSO ( Daniel Pereira ), who will be attending the conference. We look forward to catching up with old friends and sharing our updates.

Our CSO, Daniel Pereira , will be attending #AACR24 . Reach out if you’d like to connect and learn more about the exciting research and drug development happening here at CrossBridge Bio . We’re building an exciting pipeline using our ADC platform. You’ll see the full team at #ASCO .

Our scientific co-founder's ( Kyoji Tsuchikama ) review article on next-gen #ADCs is featured on the front cover of Nature Review Clinical Oncology's latest issue! The review article is free to access and download until the end of #AACR24 (April 11)! https://lnkd.in/dGCM_Sv2 #cancerresearch #cancerawareness #drugdiscovery #nextgenADCs

CROS

COM:CROSSBRIDGEBIO

CrossBridge Bio